Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › BioNTech's Personalized Cancer Vaccine, Tecentriq Yield Few Responses but Promising Immune Activity

BioNTech's Personalized Cancer Vaccine, Tecentriq Yield Few Responses but Promising Immune Activity

Jun 22, 2020
|
Charlotte Hu

This story has been updated with additional comments from Elaine Mardis during the plenary clinical trials session of the AACR annual meeting. The headline has also been updated.

NEW YORK − BioNTech's personalized cancer vaccine RO7198457 combined with the PD-L1 inhibitor atezolizumab (Genentech's Tecentriq) appears to be active and well tolerated in patients with solid tumors, according to new data presented at the second virtual session of the American Association for Cancer Research's annual meeting last Friday.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Cancer

  1. Vividion Therapeutics Raises $135M in Series C Funding

  2. CAR T-Cell Resistance Mechanism Shows Need for Multi-Antigen Targeted Immunotherapy Strategies

    Premium

  3. European Groups Find Inequitable Access to Quality Cancer Biomarker Testing

  4. Syapse Plans Deeper Dive Into Large Health Systems for Data-Driven Cancer Insights

    Premium

  5. FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.